Nonalcoholic fatty liver disease (NAFLD) is currently a major health problem, affecting more
than onequarter of adults in the world, 60% of diabetic patients and 90% of obese people …

In the latter years in hepatology, due to new, very potent antiviral drugs that can eradicate or
control viral replication in chronic hepatitis C and B patients, witnessed a change in focus …

The incidence of non-alcoholic fatty liver disease (NAFLD), a common chronic liver disease,
is increasing yearly. With increasing degrees of liver steatosis, NAFLD can progress to …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The
prevalence in patients with type 2 diabetes mellitus is between 55–80%. The spectrum of …

Non-alcoholic fatty liver disease (NAFLD) affects almost one quarter of adults worldwide,
and its progressive subtype, non-alcoholic steatohepatitis can progress to advanced …

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the United
States. While the American Association for the Study of Liver Diseases guidelines define …

Nonalcoholic fatty liver disease (NAFLD) is entering a new era in terms of diagnosis and
conceptualization. The term NAFLD is considered to not reflect current knowledge …

AFLD represents a spectrum of diseases related to excessive fat deposition in the liver,
ranging from simple steatosis (ie, non-alcoholic fatty liver, NAFL) to nonalcoholic …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver
disease. The progressive subtype of NAFLD or nonalcoholic steatohepatitits (NASH), may …

Rationale and Objectives Marked liver steatosis, steatohepatitis, and significant fibrosis are
risk factors for unfavorable outcomes in non-alcoholic fatty liver disease (NAFLD). In this …